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ABSTRACT 
 
This study focuses on women with both pre-eclampsia and Human Immunodeficiency Virus 
(HIV).  Pre-eclampsia is a pregnancy-specific syndrome that occurs after 20 weeks gestation.  
Thrombocytopenia is the most common haematological abnormality in pre-eclampsia.  
Further, studies suggest that the immunological mechanism plays some role in the aetiology of 
pre-eclampsia.  The immunological hallmark of HIV infection is a progressive decline in the 
number of CD4 T lymphocytes and significant haematological abnormalities are also common 
in HIV-infected individuals i.e. anaemia, thrombocytopenia and leukopenia.  The study 
population comprised of two groups i.e., pre-eclamptic HIV-positive African women and pre-
eclamptic HIV-negative African women as the control group.  Samples were analysed for 
haematological parameters (full blood count) and immunological markers (flow cytometry).  
There was no statistical significance in the following parameters: RBC, Hb, haematocrit, 
MCV, MCH, MCHC, platelets, MPV, WBC, lymphocytes, neutrophils, eosinophils, 
monocytes, basophils and CD8.  There was a statistical difference in the CD3 and CD4 counts 
between both the groups.  However, the CD3 and CD4 counts were within the normal range in 
the HIV-negative pre-eclamptic group and even thoug CD3 decreased, it was still within the 
normal range in the HIV-positive pre-eclamptic group, with CD4 decreasing below the normal 
range in the HIV-positive pre-eclamptic group.  This suggests that immune mechanisms 
involving CD estimations do not play a role in pre-eclampsia since the decrease in the counts 
can be solely attributed to HIV infection.  Results obtained in this study do not show any 
severe haematological or immunological abnormalities when women have both pre-eclampsia 
and HIV infection.   
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Physiologically women have an enhanced vulnerability or predisposition to disease. This 
vulnerability is increased if a woman is poor as thi  reduces her opportunity to access the 
required medical interventions. Taken together, the health hazards associated with being 
female are widely underestimated.  Economic and cultural factors may limit women’s 
access to clinics and healthcare workers.  Further to this, the World Health Organisation 
(WHO) reports that less is spent on healthcare for women and girls worldwide.  The World 
Health Report showed that, globally, the leading causes of death among women are Human 
Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), malaria, 
complications of pregnancy (hypertension, ectopic pregnancies, pre-eclampsia) and 



















Hypertension is one of the most common medical disor ers in pregnancy and is associated 
with approximately 10% - 16% of all pregnancies.  It is the leading cause of maternal, 
foetal and neonatal morbidity and mortality worldwie (Allen et al., 2004).  The limited 
understanding of the pathogenesis of these diseases is compounded by the lack of early 
diagnostic tests available to identify women at an increased risk for pregnancy-induced 
hypertension (Wolf et al., 2002 (a)). 
 
The normal blood pressure (BP) of a healthy adult is ≤ 120/80 millimeters of mercury 
(mmHg).  Hypertension in pregnancy is defined by a systolic blood pressure (SBP) of 
140mmHg or above and a diastolic blood pressure (DBP) of 90mmHg or above, on two 
occasions 6 hours apart (Sibai, 2001).  Patient anxiety, physical stress, apprehension and 
excitement can cause transient elevations in BP, therefore it is necessary to confirm 
elevated readings on two consecutive occasions (Helewa et al., 1997).   
 
During healthy pregnancy, the DBP falls by 7mmHg – 10mmHg during the first 10 weeks 
and decreases further until around the 20th week where it is at its lowest level about 
55mmHg (Reif, 2003)..  The decease in SBP is smaller (Figure 1.1).  This trend of 
decreasing BP is not found in pregnancies complicated by hypertension and therefore its 
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Table 1.1: Classifications of pregnancy-induced hypertensive disorders 
 
Diagnosis Definition 
1. Chronic Hypertension 
 
a) Essential   Hypertension: Occurring before pregnancy or 
within the first 20 weeks of gestation, does not resolve within 
three months postpartum 
b) Secondary Hypertension: Secondary to conditions such as 
renal disease, pheochromocytoma and Cushing syndrome 
2. Gestational 
Hypertension 
Hypertension after 20 weeks gestation, without the appearance 
of proteinuria or any other signs/symptoms of pre-eclampsia, 




Mild to severe hypertension diagnosed after 20 weeks 
gestation, returning to normal within three months po tpartum, 
with one or more of the following: 1. Proteinuria (≥ 0.3g/day 
or a dipstick result ≥ 1+), 2. Increase in serum creatinine levels 
(> 1.2 mg/dL), 3. Platelet count < 100 000 cells/mm3, 4. 
Evidence of microangiopathic haemolytic anaemia, 5. 
Elevated hepatic enzymes, 6. Headaches, 7. Blurred vision or 
abdominal pain, 8. Intrauterine growth retardation (IUGR) 
Eclampsia: Defined by seizures/convulsions with no k wn 
cause 
4. Pre-eclampsia 
Superimposed on Chronic 
Hypertension 
Pre-eclampsia in women who already have pre-existing 
chronic hypertension 
 
Modified from National High Blood Pressure Education Program Working Group, 2000 
 







































Figure 1.2: Diagnosis of hypertensive disorders (Reif, 2003) 
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1.2 PRE-ECLAMPSIA 
 
Eclampsia was first recognised almost 2000 years ago s seizures occurring during 
pregnancy that abated postpartum.  In the late 1800’s, the presence of proteinuria and 
increased BP was associated with eclampsia and its occurrence before the onset of 
eclampsia was noted.  This led to the term pre-eclampsia, which meant that even in the 
absence of seizures, maternal and foetal risk was increased due to the presence of 
proteinuria and increased BP.  For nearly a hundred years, research focused on increased 
BP despite the knowledge that it did not pose a major risk to both mother and child but 
rather was a marker of a multisystemic syndrome (Roberts et al., 2003 (b)).  In recent 
years, the understanding on the pathophysiology of pre-eclampsia has increased but its 
cause remains unknown. 
 
Pre-eclampsia is a pregnancy-specific syndrome that occurs after 20 weeks gestation or 
earlier in instances of trophoblastic disease such as ydatidiform mole (NHBPEP, 2000), a 
condition in which genetically abnormal tissue proliferates in the absence of a foetus 
(DiFederico et al., 1999).  It is defined by an increased BP of SBP ≥ 140mmHg and DBP ≥
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Most of the pathophysiological changes occur before clinical symptoms are present and 
since multiple organs are affected, the clinical presentation can appear in a variety of ways.  
Therefore, there is no standard test or group of tests that is able to successfully detect pre-
eclampsia at an early stage.  Laboratory tests are used instead to differentiate between pre-
eclampsia and chronic or gestational hypertension and also to ascertain the severity of pre-
eclampsia (Peters & Flack, 2004).  Efforts to identify an ideal screening or predictive test 
for pre-eclampsia have been unsuccessful thusfar (NHBPEP, 2000).  
 
The 24-hour urine collection (once the bladder is emptied, all urine that is passed over a 24 
hour period is collected) gives the most accurate diagnosis and is therefore recommended 
to quantitate proteinuria.  Dipstick measurement should be used when a rapid 
determination is required (Sibai, 2001).  In the absence of proteinuria, pre-eclampsia is 
suspected when increased BP is present together with headaches, blurred vision, abdominal 
pain, thrombocytopenia (low platelet count) and abnormal liver enzymes (NHBPEP, 2000). 
 
Eclampsia occurs when pre-eclampsia progresses to a life-threatening convulsive phase 
that usually occurs after mid-pregnancy or during delivery.  Convulsions occurring during 
the first 48 hours postpartum have also been observed (Roberts et al., 2003). 
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1.2.1 Incidence and Risk Factors 
 
The incidence rate of pre-eclampsia in healthy nulliparous women is between 2% - 7% 
with increased rates in women with twin gestation (14%) and those with previous pre-
eclampsia (18%) (Sibai, 2003).  Geographical and racial differences in incidence have been 
reported but this may be attributed to socio-economic status and poor medical care (Sibai, 
2001).   
 
Risk factors for pre-eclampsia include: 
 
 Age > 40 years (Sibai, 2003; Peters & Flack, 2004), 
 Nulliparity (Sibai, 2003; Peters & Flack, 2004) , 
 Obesity (Sibai, 2003; Peters & Flack, 2004), 
 African ethnicity (Sibai, 2003; Peters & Flack, 2004), 
 Pre-existing chronic hypertension or renal disease (Sibai, 2003; Peters & Flack, 
2004), 
 Diabetes mellitus (Sibai, 2003; Peters & Flack, 2004), 
 Multi-foetal gestation (Sibai, 2003; Peters & Flack, 2004), 
 Family history of pregnancy-induced hypertension (Sibai, 2003; Peters & Flack, 
2004), 
 Pre-eclampsia in previous pregnancy (Sibai, 2003; Peters & Flack, 2004), 
 Thrombophilias (Sibai, 2003; Peters & Flack, 2004), 
 Abnormal uterine Doppler studies at 18 and 24 weeks (Sibai, 2003; Peters & Flack, 
2004). 
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Vatten and Skjaerven, (2003) showed that changing partners between the first two births 
increases the risk of infant mortality, preterm birth and low birth weight for the second 
birth, which are foetal manifestations associated with pre-eclampsia.  This may be due to 
the long intervals between both births and therefore the increase in maternal age, a risk 
factor of pre-eclampsia.  Poor pregnancy outcomes related to change of partner have 
focused on the effects attributed to change of patern l antigens or genes.  There is also the 
“selection hypothesis” where women who change partners are a selected group with 
lifestyle and behavioural characteristics that increase their risk to develop pre-eclampsia.   
 
Trogstad et al., (2001) showed a reduced risk of pre-eclampsia in the second pregnancy in 
women with a change in paternity after controlling the time interval between the two 
births.  However, increased risk of pre-eclampsia was observed in women with no previous 
pre-eclampsia and long pregnancy intervals.  Since i reasing maternal age was accounted 
for, the increased risk may have been due to enviromental influences such as infections.  
A long interval between deliveries increases a mother’s risk to acquire infections that may 
re-activate during pregnancy.  Therefore, it was hypothesised that some women may 
develop pre-eclampsia as a consequence of a coinciding infectious stimulus adding to the 
inflammatory burden of a normal pregnancy. 
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1.2.2 Aetiology and Pathophysiology  
 
Pre-eclampsia is a syndrome that affects almost all maternal organ systems.  The 
pathophysiology is characterised by activation of the coagulation system and perturbations 
in many humoral and autacoid systems related to volume and BP control.  The pathological 
changes are ischemic in nature and affect the placent , kidney, liver and brain (NHBPEP, 
2000). 
 
The placenta is the key component in pre-eclampsia (Figure 1.3) (NHBPEP, 2000).  Pre-
eclampsia only occurs in the presence of placenta ad resolution begins with delivery of 
the placenta.  In cases of extra-uterine pregnancy, persistent pre-eclamptic signs and 
symptoms are observed following delivery of the foetus without the placenta (Roberts et 




















Figure 1.3: The placenta unites the foetus to the maternal uterus (Modified from  
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The pathophysiology of pre-eclampsia can be divided into two stages.  The first stage 
(placental ischemia) is reduced placental perfusion that is secondary to abnormal 
implantation and development of the placental vascul ture (Stage 1).  The second stage 
(maternal syndrome) is the maternal response to the reduced placental perfusion 
characterised by inflammation and maternal endothelial dysfunction (Stage 2) (Society for 
Paediatric Pathology, 2003).   
 
Decreased placental perfusion is thought to result in oxidative stress at a placental level. 
With subsequent release of trophoblastic debris, apoptotic cells and a variety of substances 
which lead to maternal endothelial dysfunction and  sterile inflammatory response.  The 
link between the two stages, however, is still being investigated since placental factors are 
not exclusively responsible for the maternal syndrome of pre-eclampsia.  Furthermore, it is 
uncertain as to how immune mechanisms link into this hypothesis.  Intrauterine growth 
restriction and pre-term births are associated with abnormalities in Stage 1, without the 
occurrence of the maternal syndrome (Society for Paediatric Pathology, 2003). 
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1.2.2.1 Stage 1: Placental Ischemia  
 
The formation of the placenta is the apposition of foetal and maternal tissues to allow 
physiological exchange.  Foetal and maternal tissues come into intimate contact at several 
sites such as the syncytiotrophoblast intervillous space, chorion laeve decidua parietalis 
and the placental bed (Society for Paediatric Pathology, 2003).  The resulting area of mixed 
origin between the placenta and decidua is called th  maternofoetal junctional zone (Figure 
1.4). The basal plate forms the bottom of the intervillous space and attaches to the placenta 
after delivery.  The placental bed attached to the uterine wall and remains in the uterus 
after delivery (Kaufman et al., 2003).  The decidua and myometrium make up the placent l 
bed, which contains the origins of the spiral arteries (Society for Paediatric Pathology, 
2003). 
 
During early human pregnancy, extravillous trophoblast derived initially from the primitive 
cytotrophoblast shell and the anchoring villi (columns) infiltrate into the decidua and 
superficial myometrium in the placental bed.  These cytotrophoblasts that invade the 
uterine interstitium comprise the interstitial troph blast (Society for Paediatric Pathology, 





















Figure 1.4: Interstitial and endovascular trophoblast invasion in < 6 weeks normal  
                    gestation. Blue = foetal tissues, red = maternal tissues (Modified from     
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Cytotrophoblast cells (endovascular cytotrophoblast) invade the uterine spiral arteries 
(terminal branches of the uterine artery) replacing the endothelial layers of the vessels 
resulting in the destruction of the medial elastic, muscular and neural tissues.  By the end 
of the second trimester of pregnancy, the uterine spiral arteries are lined entirely by 
cytotrophoblast and endothelial cells are absent in the endometrial or superficial 
myometrial regions (Figure 1.5).  These changes result in the formation of a low resistance 
arteriolar system, which increases the blood supply to the foetus (Mushambi et al., 1996; 
Granger et al., 2001).  The remodelling of the uterine spiral arteries is important for normal 































Figure 1.5: Interstitial and endovascular trophoblast invasion in > 20 weeks normal  
                    gestation.  Blue = foetal tissues, red = maternal tissues (Modified from       
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In pre-eclampsia and IUGR trophoblastic invasion is incomplete (Figure 1.6).  Invasion of 
the uterine spiral arteries is limited to the proximal decidua with 30% - 50% of the spiral 
arteries of the placental bed escaping endovascular trophoblast remodelling (Mushambi et
al., 1996; Granger et al., 2001).  The cause of this may be failure of cytotrophoblast cells to 
express the adhesion molecules necessary for normal re odelling of the maternal spiral 
arteries (NHBPEP, 2000).  These cells enable the trophoblast to adhere to the extracellular 
matrix, form colonies and target cells in the vessel wall (Kaufman et al., 2003).  However, 
well-known maternal risk factors for pre-eclampsia and IUGR (renal disease, diabetes, 
obesity and stress) render it unlikely that trophoblastic failure is the sole pathogenic 






























Figure 1.6: Interstitial and endovascular trophoblast invasion in >20 weeks                                 
pre-eclampsia/IUGR.  Blue = foetal tissues, red = maternal tissues 
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Medical conditions associated with microvascular disease, such as hypertension, diabetes 
and collagen vascular disease increases the risk of pre-eclampsia, further supporting the 
theory that impaired placental perfusion is an important event leading to pre-eclampsia 
(Roberts et al., 2003).  Women with pre-eclampsia have a distinctive lesion, acute 
atherosis, found on the spiral arteries, which results in the obstruction of the decidual 
vessels as well as increased frequency of placental necrosis, both of which can lead to 
decreased placental perfusion and placental hypoxia  (Gr nger et al., 2001; Peters & Flack, 
2003).  In addition, placental hypoxia in pre-eclampsia is supported by reports of decreased 
clearance rates of various radioactive compounds and steroids by the pre-eclamptic 
placenta (Granger et al., 2001).  
 
 
1.2.2.2 Stage 2: Endothelial Dysfunction  
 
The vascular endothelium has important functions including maintenance of fluid 
compartments, prevention of intravascular coagulation, modification of contractile function 
in smooth muscle wall and maintenance of immune and inflammatory response (Mushambi 
et al., 1996).  It has been suggested that the release of fact rs from the abnormal placenta, 
in response to ischemia, results in endothelial dysfunction of the maternal circulation 
(Figure 1.7) (Granger et al., 2001).  Evidence supporting this hypothesis has been 
demonstrated when sera from women destined to develop or manifesting pre-eclampsia 
have shown to be cytotoxic to endothelial cells in culture (Laragh & Brenner, 1995).   
 















Figure 1.7: Potential mechanisms whereby reduced placental perfusion may lead to  
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High levels of circulating substances known to be markers of endothelial damage have 
been reported in women who develop pre-eclampsia, further supporting the theory that pre-
eclampsia is an endothelial cell disorder (Granger et al., 2001).  An imbalance of 
anticoagulation and procoagulation forces are found in pre-eclampsia whilst increases in 
proteins of the coagulation cascade have been reported in women with pre-eclampsia.  
Circulating levels of fibronectin and plasma thrombo odulin , an anticoagulation factor, 
are significantly increased in women with pre-eclampsia as early as 20 weeks and 24 
weeks of pregnancy respectively.  These levels increase relative to the severity of the 
disease and therefore can act as biomarkers reflecting the severity of the disorder.  Von 
Willerbrand factor, another coagulation cascade factor, is also elevated in women with pre-
eclampsia (Granger et al., 2001). 
 
Enhanced platelet activation and increased levels of platelet endothelial cell adhesion 
molecule–1 (PCAM-1) also occurs in women who develop pre-eclampsia.  Other adhesion 
molecules, vascular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 
(ICAM-1) and E-selectin, are also significantly elevated in women who develop pre-
eclampsia.  Plasma levels of ICAM-1 and VCAM-1 have shown to be elevated at 3 to 15 
weeks before the onset of clinical manifestations (Granger et al., 2001). 
 
Evidence of endothelial dysfunction as an early event in pre-eclampsia suggests that it is a 
possible cause and not a result of the pregnancy-specific disorder and many markers may 
function as predictors of the syndrome in women who develop pre-eclampsia (Granger et 
al., 2001). 
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1.2.3 Maternal Manifestations 
 
The maternal risks associated with pre-eclampsia are convulsions, cerebral haemorrhage, 
abruptio placentae with disseminated intravascular co gulopathy, pulmonary oedema, renal 
failure, liver haemorrhage and death (Sibai, 1996).  
 
Hypertension is common among women with pre-eclampsia during the second half of 
pregnancy but vasoconstrictive influences may be present earlier.  Numerous surveys 
suggest that women who eventually develop pre-eclampsia have BP’s falling slightly 
higher in the normal ranges as early as the second trimester (NHBPEP, 2000).  Blood 
pressure in pre-eclampsia is characterised by a reversal of the vasodilatory characteristics 
of uncomplicated pregnancy which results in a marked increase in peripheral resistance 
(Peters & Flack, 2004).  Normally the vasculature of the normotensive woman manifests a 
decreased pressor response to several vasoactive peptides and amines, especially to 
angiotensin II.  However, the vessels of women with pre-eclampsia become hyper-
responsive to these hormones (NHBPEP, 2000) and the abnormal pressor response to 
angiotensin II has shown to be increased significantly by 22 weeks gestation in women 
who later develop pre-eclampsia (Mushambi et al., 1996). 
 
Blood pressure also behaves differently in women with pre-eclampsia, who can have 
highly labile pressures and could experience a flattening or reversal of normal circadian BP 
rhythms, with their highest values recorded at night (Peters & Flack, 2004).  Blood 
pressure returns to normal postpartum, often within t e first few days or two to four weeks 
in severe cases.  The mechanisms underlying vasocontriction and altered vascular 
reactivity in pre-eclampsia remain obscure.  Research has focused on the renin-angiotensin 
   25 
system, catecholamines, prostaglandins and nitric oxide and endothelial cell products and 
other circulating factors which may influence volume or vascular reactivity and 
permeability (NHBPEP, 2000). 
 
1.2.4 Foetal Manifestations 
 
The foetal risks associated with pre-eclampsia are severe growth restriction, low birth 
weight, hypoxemia, acidosis, preterm birth and perinatal death (Sibai, 1996).  Preterm birth 
is associated with increased mortality and morbidity rates and long-range neurological 
disability.  Fifteen percent of all preterm births are a consequence of early deliveries during 
pre-eclampsia to prevent further deterioration of the mother and foetus (Roberts et al., 
2003).   
 
The conditions of foetal growth are controlled mainly by genetics during the first trimester 
of pregnancy and are affected by the natural enviroment in the second and third trimesters 
of pregnancy (Yamada et al., 2004).  Impairment of placental perfusion caused by 
placental disease and vasospasm has been suggested to be one of the major reasons for the 
high incidence of foetal death, IUGR, SGA infants and perinatal mortality.  In addition, the 
state of the mother (severe pre-eclampsia or the possibility of progression to eclampsia) 
frequently requires early termination of the pregnancy (Mushambi et al., 1996).  
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Intrauterine growth restriction is the primary cause of low birth weight and perinatal 
morbidity.  It is associated with an increased risk of cerebral palsy, short stature and sub-
normal intellectual and psychological performance during later childhood (Yamada et al., 
2004).  Odegard et al. (2000) showed significant IUGR in severe and early-onset pre-
eclampsia and an increased risk in women with recurnt pre-eclampsia of having an SGA 
infant.  Allen et al. (2004) also demonstrated an increased risk among women with 
hypertensive disorders of having an SGA infant with the risk higher in hypertensive 
women with a twin pregnancy.  Hypertensive women were shown to be at a significantly 
higher risk of stillbirth compared with women having ormotensive pregnancies.   
 
Positive correlations between pregnancy oestrogens and foetal size have been reported and 
decreases in serum oestradiol levels have been found in women with foetal growth 
restriction.  Oestrogens are known to stimulate cell proliferation and placenta growth and 
therefore supports the link between abnormal placent l development and foetal growth 





Management of pre-eclampsia requires early diagnosis and close medical supervision with 
delivery being the best cure.  Management is based on the initial evaluation of maternal 
and foetal well-being, the severity of the disease nd the length of gestation (Sibai, 1996).   
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Women with mild pre-eclampsia require close observation in the hospital.  Outpatient 
management should be considered if compliance is expected to be good, hypertension is 
mild and the foetus is normal.  The management should include close monitoring of the 
mother’s BP, weight, proteinuria and platelet count.  Bed rest is recommended with the 
proposed results being reduction of oedema, improved foetal growth, prevention of 
progression to severe pre-eclampsia and improved outcomes of pregnancy (Sibai, 1996).   
 
In women with severe pre-eclampsia, hospitalisation and delivery is strongly recommended 
when there is evidence of impending eclampsia, multi-organ dysfunction, and foetal 
distress or when severe pre-eclampsia develops after three weeks.  During hospitalisation, 
anti-hypertensive drug therapy is administered if required with the aim being to keep 
systolic BP between 140 – 155 mmHg and diastolic BP between 90 – 105 mmHg (Sibai, 
2003).  Short-acting antihypertensive agents, hydralazine, labetol and nifedipine are 
commonly used to control very high BP in women with severe hypertension during 
pregnancy (Magee t al., 2003). 
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1.2.6 Pre-eclampsia in South Africa 
 
Pre-eclampsia tends to be more severe and life-threatening in developing countries since 
little or no antenatal care is available to low-to-middle income people. Pre-eclampsia 
therefore remains undiagnosed until the condition has reached an advanced or dangerous 
stage.  In addition, these women are more likely to have more underlying health and social 
problems which increases their risk of developing pre-eclampsia.  These problems include 
chronic hypertension, malnutrition, anaemia, chronic malaria and a tendency to have many 
babies, starting at a young age (Medical Research Council, 2002). 
 
Hypertensive disorders are the most common direct cause of maternal deaths in South 
Africa (SA).  The recent Saving Mothers report (200 – 2004) indicated that hypertensive 
disorders contributed 19.1% (n=628) of all deaths and pre-eclampsia/eclampsia syndrome 
accounted for 518 (82.5%) of deaths in SA (Table 1.2).  However, the magnitude of the 
problem resulting from hypertensive disorders of pregnancy might be under reported due to 
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Table 1.2: Primary obstetric causes of death associated with hypertensive disorders in  
       pregnancy  
 
Types of Disorders N % 
Eclampsia 347 55.3% 
Proteinuric Hypertension 171 27.2% 
Chronic Hypertension 37 9.2% 
Haemolysis, Elevated Liver Enzymes, Low Platelets (HELLP syndrome) 70 11.1% 
Rupture of Liver 3 0.5% 
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1.3 HUMAN IMMUNODEFICIENCY VIRUS 
 
Human Immunodeficiency Virus belongs to a group of viruses called retroviruses (Figure 
1.8).  Two distinct viruses, HIV types 1 and 2 (HIV-1, HIV-2), cause AIDS.  Human 
Immunodeficiency Virus - 1 is responsible for the great majority of infections globally, 
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Human Immunodeficiency Virus is present in the blood, semen and vaginal fluids of 
infected people.  Although sophisticated laboratory echniques are able to isolate the virus 
from other body fluids of infected people (such as s liva or tears), the level of the virus in 
these fluids is too low to be infectious.  HIV is transmitted: 
 
 through unprotected sexual intercourse; mainly heterosexual in Sub-Saharan Africa,  
 through blood to blood contact: by sharing injecting equipment among drug users, 
by blood transfusion from infected people and needl-stick injuries amongst health 
workers 
 vertical transmission: from HIV positive women to her baby during the course of 
pregnancy, birth and breastfeeding (AIDSmap Treatmen  and Care, 2005). 
 
The chances of a woman being infected by one act of sexual intercourse with an HIV 
positive man are about 1 in 100.  The chances of a man being infected by one act of sexual 
intercourse with an HIV positive woman are about 1 in 1000 but this probability may 
increase considerably if one of them has a sexually transmitted disease (STD).  The STDs 
act as co-factors in HIV transmission by increasing susceptibility to HIV (Singhal & 
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Human Immunodeficiency Virus is a lentivirus.  In common with all retroviruses, 
lentiviruses have three major genetic loci (gag, pol, env) that encode the core proteins, the 
reverse transcriptase and integrase and the envelope pr teins respectively.  The lentiviruses 
are distinguished from other retroviruses by several ch racteristics:  
 
 They possess 6 unique accessory genes that encode non-structural proteins;   
 The viral attachment protein (the surface envelope protein, SU) binds to the clusters 
of differentiation4 (CD4) molecule that is found on the CD4 subset of T 
lymphocytes and on monocytoid cells and this determines their cellular host range;  
 They are capable of replicating in non-dividing cells as well as dividing cells;  
 They cause lifelong infections that are associated with a number of chronic diseases 
including AIDS but they do not encode oncogenes;  
 They are strictly exogenous viruses and host genomes do not include copies of their 





The transmission of an animal virus to a human host(zoonotic transmission) enables the 
rapid spread of a virus beyond the geographic range of its original animal host.  It is 
believed that the most serious viral epidemic resulting from zoonotic transmission is 
caused by HIV.  Exactly when and how the Simian Immunodeficiency Virus (SIV) was 
transmitted from a non-human primate to humans and began to diversify, resulting in the 
emergence of HIV’s is still under investigation (Hillis, 2000).   
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The HIV-1 virus was first identified in 1983 at the National Cancer Institute in Bethesda, 
Maryland by Dr Robert Gallo and other medical scientists.  At about the same time, Dr Luc 
Montagnier of the Pasteur Institute in Paris isolated HIV-2 from AIDS patients (Singhal & 
Rogers, 2003). 
 
Scientists have tried to trace the origins of the epid mic.  A dozen AIDS cases were 
retrospectively identified in 1978 – 1979.  Scattered cases of HIV infection or AIDS were 
identified in the United States and Haiti from 1972 – 1976.  The earliest known case of 
HIV-1 has been identified in one of 1213 stored blood samples that were gathered in 1959 
in Africa.  The individual, designated “L70”, was an adult male living in Kinshasa, 
Democratic Republic of Congo.  Using sophisticated mathematical models and computer 
tools and knowing that L70’s infection probably had ancestors in the B, D and F subtypes 
of HIV-1, biologists estimate that the first HIV case occurred in Africa in the 1930’s 
(Singhal & Rogers, 2003).   
 
When AIDS first emerged as a clinical problem in the 1980’s, many patients died early 
from acute illnesses such as pneumonia and tuberculosis.  Cumulative experience and 
increased awareness have led to the use of prophylaxis, early diagnosis and more effective 
treatment and management of HIV infection and AIDS (Wood et al., 1997). 
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1.3.2 Virus-Cell Interactions 
 
The entry of HIV into permissive host cells is a multi-step process that involves a primary 
receptor and a co-receptor (Figure 1.9).  The primary receptor is CD4, an immunoglobulin 
superfamily molecule, expressed on two major cell types, the CD4 subset of T lymphocytes 
and the cells of the monocyte lineage.  The co-receptor is one of several members of the 
chemokine family of molecules, particularly CCR5 expressed on T lymphocyte and T-cell 
lines (TCL).  Initially, the viral attachment protein (SU protein) binds to CD4, which 
triggers a conformational change in the SU protein hat leads to binding to the co-receptor.  
Binding to the co-receptor triggers a second change i  the transmembrane (TM) envelope 
proteins resulting in the approximation of the N-terminal domain of the TM protein to the 
plasma membrane of the cell.  A hydrophobic fusion peptide at the N-terminal domain of 
the TM protein inserts into the plasma membrane, leading to fusion between the viral 
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Human Immunodeficiency Virus commandeers host cells, turning them into factories 
churning out virus particles.  When HIV infects a cell, reverse transcriptase copies the 
ribonucleic acid (RNA) into double-stranded deoxyribonucleic acid (DNA), which is then 
spliced into the host DNA.  This new integrated DNA (the HIV provirus) manufactures 
viral proteins and RNA copies of the virus genome.  Proteins and RNA are brought 
together to form new HIV particles, which bud from the cell and go onto infect other host 
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Human Immunodeficiency Virus replicates slowly in permissive cells.  If the infected 
lymphocyte is actively dividing, then viral replication proceeds at a maximal rate.  If the 
infected T cell is resting, the provirus can enter th  nucleus and integrate but remains latent 
until the T cell begins to divide, when HIV replication proceeds (Nathanson et al., 2002). 
 
The hallmark of HIV infection is a progressive decline in the number of CD4 T 
lymphocytes over many years.  CD4 T lymphocytes act as “helper cells” for the induction 
of both cellular (CD8 cytolytic T cells) and humoral (antibody) immune rsponse.  
Therefore HIV infected patients are impaired in their ability to develop immune responses 
and are particularly susceptible to new infections against which they have no immunity 
(Nathanson et al., 2002). 
 
 
1.3.3 Clinical Features 
 
 Group I: Primary HIV Infection 
 
Primary HIV infection is also called the seroconversion illness or acute HIV infection.  It 
represents the stage of infection after the acquisition of the virus when antibodies are 
developing.  Some people have been found to present with symptoms at the time of 
seroconversion which includes fever, sore throat, night sweats, malaise, lymphadenopathy 
(abnormal enlargement of the lymph nodes), diarrhoea and relative and absolute 
lymphocytosis in the peripherial blood. These sever illnesses are rare (Timbury, 1994; 
Mindel & Tenant-Flowers, 2001).  Primary HIV infection is characterised by rapid viral 
replication and a dramatic drop in the T helper cell ount (Welcome Trust, 2000). 
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 Group II: Asymptomatic Infection 
 
After Primary HIV Infection, HIV antibodies continue to be detectable in the blood.  The 
amount of virus in the blood and lymphoid tissues falls to very low levels and the rate of 
HIV replication is slow but does not cease.  CD4 lymphocyte counts are within normal 
limits or generally above 350 x 106 cells/l.  This phase may persist for 10 years or moe 
(Mindel & Tenant-Flowers, 2001). 
 
 Group III: Persistent Generalised Lymphadenopathy 
 
Persistent generalised lymphadenopathy may be a presenting feature of HIV infection in a 
person who is otherwise well.  HIV related lymphadenopathy persists for at least 3 months 
(Mindel & Tenant-Flowers, 2001). 
 
 Group IV: Symptomatic HIV Infection 
 
The progression of HIV infection is a result of a decline in immune competence that occurs 
due to increased replication of HIV from sites where it has been latent.  As the disease 
progresses, infected persons suffer from constitutional symptoms, skin and mouth 
problems and haematological disorders (Mindel & Tenant-Flowers, 2001).  Progression to 
AIDS correlates with a severe decrease in the CD4 count (Timbury, 1994). 
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1.3.4 Treatment 
 
The course of HIV infection is variable and unpredictable, with a wide range of potential 
complications, rates of progression and survival.  Some patients remain free of serious 
symptoms and complications until they have reached an advanced stage of 
immunosuppresion, while others suffer debilitating malaise and fatigue or frequent non-life 
threatening complications throughout their infection.  Medical management of people with 
HIV is a balance between acute treatment and attemping to control chronic symptoms and 
conditions (Wood et al., 1997). 
 
Antiretroviral (ARV) therapy has shifted the model of care delivery from one of terminal 
care to one of chronic disease management (Levi & Kates, 2000).  Antiretroviral drugs 
inhibit the replication of HIV.  When antiretroviral drugs are given in combination, HIV 
replication and immune deterioration can be delayed an  survival and quality of life 
improved (World Health Organisation, 2006).   
 
The common classes of drugs currently available are the nucleoside reverse transcriptase 
inhibitors (NRTIs) such as zidovudine (AZT), lamivudine (3TC), abacavir, the non-
nucleoside reverse transcriptase inhibitors (NNRTIs) such as nevirapine and efavirenz2 and 
the protease inhibitors such as indinavir, ritonavir and lopinavir (Family Health 
International, 2006).  Selection of ARV treatment regimens for programmes and individual 
patients should consist of frequency of dosage, side effects, maintenance of future 
treatment options, need for storage, concurrent conditi s, viral strains and cost and access 
(World Health Organisation, 2006).   
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Several guidelines for ARV therapy concur that treatment is indicated for patients who are 
symptomatic (e.g., have thrush, fevers, thrombocytopenia or wasting), have AIDS (CD4 
cell counts of less than 200 cells/mm3 or AIDS defining conditions), who are pregnant (to 
prevent perinatal transmission).  The controversy among the guidelines revolves around the 
appropriate CD4 cell count or HIV RNA levels at which to initiate herapy in asymptomatic 
pre-AIDS patients (Khalsa, 2006). The WHO recommends that in ARV therapy 
programmes in resource-limited settings, HIV infected adolescents and adults should start 
ARV therapy when they have clinical AIDS, regardless of the CD4 count. When total 
lymphocyte count can be assessed, in addition, people with WHO stage II or III HIV 
disease should be offered treatment. When CD4 counts are available, all HIV infected 
people with less than 200 CD4 cells/mm
3 should be offered treatment (WHO, 2006). 
 
 
1.3.5 HIV/AIDS in South Africa  
 
South Africa has one of the fastest growing HIV epid mics in the world.  In SA, the 
epidemic is mainly concentrated among the African population, which makes up to 90% of 
the total population of 43 million (Singhal & Rogers, 2003).   
 
   43 
The human impact of the HIV epidemic in South Africa has been devastating and the need 
to tackle this pandemic on all fronts with new vaccines, medical interventions and 
campaigns to reduce the rate of transmission grows more urgent (Welcome Trust, 2000).  
Contributing factors to these epidemiological trends may include barriers faced by women 
in accessing care as well as financial constraints resulting in women depending on the 
public sector for the financing and delivery of the care (Levi & Kates, 2000). Refusal of 
condom use by male partners is compounded by women playing the socially submissive 
role in most relationships also contributes daily to this pandemic (Pettifor et al., 2004) 
 
Surveys amongst women attending antenatal clinics in the public sector have been 
undertaken by the South African Department of Health nnually.  These surveys provide 
the best available estimates of HIV infection among the South African population.  These 
show that SA has experienced a very rapid spread of HIV during the last decade.  In 1990, 
the first year of the survey, the prevalence was les than one percent (Dorrington et al., 
2001). 
 
The findings of the 2005 survey indicate that HIV prevalence in SA among pregnant 
women is 30.2%, compared to 29.5% observed in 2004.  HIV prevalence continues to vary 
by province as shown in Table 1.3.  KwaZulu-Natal hs the highest prevalence in South 
Africa of 39.1% in 2005.  Further to this, the Department of Health estimates that over 90, 
000 babies became infected with HIV through the mother- o-child transmission route 
(Department of Health, South Africa, 2005). 
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Table 1.3: HIV prevalence by province among antenatl clinic attendees, South 
      Africa: 2003 – 2005  
 
Province HIV Prevalence 
2003 (CI 95%) 
HIV Prevalence 
2004 (CI 95%) 
HIV Prevalence 
2005 (CI 95%) 
KwaZulu-Natal 37.5 (35.2 – 39.8) 40.7 (38.8 – 42.7) 39.1 (36.8 – 41.4) 
Mpumalanga 32.6 (28.5 – 36.6) 30.8 (27.4 – 34.2) 34.8 (31.0 – 38.5) 
Gauteng 29.6 (27.8 – 31.5) 33.1 (31.0 – 35.3) 32.4 (30.6 – 34.3) 
North West 29.9 (26.8 – 33.1) 26.7 (23.9 – 29.6) 31.8 (28.4 – 35.2) 
Free State 30.1 (26.9 – 33.3) 29.5 (26.1 – 32.9) 30.3 (26.9 – 33.6) 
Eastern Cape 27.1 (24.6 – 29.7) 28.0 (25.0 – 31.0) 29.5 (26.4 – 32.5) 
Limpopo 17.5 (14.9 – 20.0) 19.3 (16.8 – 21.9) 21.5 ( 8.5 – 24.6) 
Northern Cape 16.7 (11.9 – 21.5) 17.6 (13.0 – 22.2) 18.5 (14.6 – 22.4) 
Western Cape 13.1 (8.5 – 17.7) 15.4 (12.5 – 18.2) 15.7 (11.3 – 20.1) 
South Africa 27.9 (26.8 – 28.9) 29.5 (28.5 – 30.5) 30.2 (29.1 – 31.2) 
 
(Adapted from the Department of Health, 2005) 
N.B. The true value is estimated to fall within the two confidence limits, thus the 
Confidence Interval (CI) is important to refer to when interpreting data 
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Human Immunodeficiency Virus prevalence is different among the different age groups 
suggesting different patterns of risk (Table 1.4).  Nearly 40% of women attending antenatal 
clinics aged between 25-29 years are HIV positive.  Women in the early twenties and late 
thirties show lower rates at about 30% prevalence.  Older women and teenagers have 
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Table 1.4: HIV prevalence by age group among antenat l clinic attendees, South  





2003 (CI 95%) 
HIV Prevalence 
2004 (CI 95%) 
HIV Prevalence 
2005 (CI 95%) 
<20 15.8 (14.3 – 17.2) 16.1 (14.7 – 17.5) 15.9 (14.6 – 17.2) 
20 – 24 30.3 (28.8 – 31.8) 30.8 (29.3 – 32.3) 30.6 (29.0 – 32.2) 
25 – 29 35.4 (33.6 – 37.2) 38.5 (36.8 – 40.3) 39.5 (37.7 – 41.3) 
30 – 34 30.9 (28.9 – 32.9) 34.4 (32.2 – 36.6) 36.4 (34.3 – 38.5) 
35 – 39 23.4 (20.9 – 25.9) 24.5 (21.9 – 27.2) 28.0 (25.2 – 30.8) 
40+ 15.8 (12.3 – 19.3) 17.5 (14.0 – 21.0) 19.8 (16.1 – 23.6) 
 
(Adapted from the Department of Health, 2005) 
 
N.B. The true value is estimated to fall within the two confidence limits, thus the 
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Gender power inequities, economic vulnerabilities and inconsistent condom use play a key 
role in the HIV epidemic.  In SA, multiple partnerships are condoned and even encouraged 
for men, while women are expected to be monogamous and unquestioning of their 
partner’s behaviour.  Sexual refusal or negotiation by women may result in suspicions of 
infidelity and carry the risk of violent outcomes.  In the context of poverty, partnerships 
with men who can provide financially are essential, r nsactional relationships in which sex 
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1.4 MANIFESTATIONS         OF         PRE-ECLAMPSIA         AND         HUMAN   





Thrombocytopenia is the most common haematological abnormality in pre-eclampsia 
occurring in one-third of all patients.  Platelet counts < 100 000 cells/mm3 indicate severe 
disease, which occurs in only 15% of women (Mushambi et al., 1996).  Levels may 
continue to fall if delivery is delayed and therefor  increases the risk of bleeding.  The 
cause of thrombocytopenia is unclear.  Enhanced platelet aggregation and destruction may 
be due to endothelial damage and increments in circulating fibronectin, laminin and 
preprocollagen type II (markers of endothelial cell injury) have been described which may 
correlate with increases in products of platelet granules, the increments consistent with 
activation (Laragh & Brenner, 1995). 
 
Thrombocytopenia is linked to DIC which is characteris d by the widespread activation of 
coagulation, which results in the intravascular fo mation of fibrin and ultimately 
thrombotic obstruction of small and midsize vessels (NHBPEP, 2000).   There are many 
reports documenting increased consumption of various clotting components as well as 
decreases in inhibitors of coagulation.   
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Thrombocytopenia is a common finding in HIV infection and increases as the disease 
progresses.  It is an immune mediated destruction resulting in a severe decrease in platelets 
and abundance of megakaryocytes in the bone marrow.  Suggested mechanisms include 
circulating platelets being damaged IgG, immune complexes or antibodies to specific 
platelet surface antigens (McPhedran, 1999). 
 
During pregnancy, the foetal demand for iron increases maternal daily iron requirements 
from =/- 1 to 2.5 mg/day in early pregnancy and 6.5 mg/day in the third trimester.  This 
demand by the developing foetus may result in the mother to develop iron deficiency 
anaemia (Steer, 2000).  Iron deficiency is considere  the most important cause of low 
haemoglobin concentration and may have independent effects on other maternal, 
pregnancy and infant outcomes such as immunity, pre-eclampsia, maternal mortality, 
malformation, foetal loss, prematurity and IUGR (Friis et al., 2001). 
 
Anaemia is the most common finding in HIV infection, particularly in people with 
advanced stages of HIV and can be defined as a reduction below normal of the 
haemoglobin concentration and red blood cell mass (Kline, 2005).  Usually normocytic 
normochromic anaemia manifests.  A persistently low haemoglobin concentration is 
predictive of a poor outcome.  The possible causes of anaemia include:  
 
 Drug-induced anaemia 
 Opportunistic infections such as tuberculosis  
 Anaemia caused by bone marrow infections 
 Decreases in vitamin B12, folate and iron (Northfelt, 1998). 
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During normal pregnancy upregulation of the inflammatory cascade and increase in white 
cell count occurs (Sattar & Greer, 2002).  Leukopenia (decrease in white blood cells) is 
frequently associated with HIV infection which result  from the parallel decline in the 
three most numerous kinds of leukocytes: neutrophils, lymphocytes and monocytes.  The 
main causes of leukopenia are not known, although HIV invasion of myeloid precursors or 
of cells producing granulocyte-stimulating cytokines have been suggested.   Leukopenia 
tends to worsen gradually with progression of HIV infection with sudden plunges in the 





The vascular endothelium plays a role in the maintenance of immune response therefore 
endothelial dysfunction during pre-eclampsia results in immunological alterations.  Further 
to this, various studies suggests that the immunological mechanism plays some role in the 
aetiology of pre-eclampsia.  Studies have found a decrease in the functional activities of 
the natural killer (NK) cells and an increase in the serum levels of immunoglobulin (Ig)E, 
antinuclear antibodies (ANA) and antimitochondrial antibodies (AMA) (Cetiner et al., 
1998).   
 
Cetiner et al., (1998) also reported conflicting results from other studies with regards to 
CD4/CD8.  Studies have demonstrated that the rates of CD4 in pre-eclamptic women begin 
to decrease in the early stages of pregnancy before the occurrence of pre-eclampsia and 
normal levels are only reached several weeks after delivery.  In another study, it was found 
that the rates of CD4/CD8 in pre-eclamptic women were lower when compared to normal 
pregnant women.   
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There are also immune hypotheses to explain abnormal placentation in pre-eclampsia.  It is 
suggested that a breakdown of the usual adaptations in the immune system required to 
sustain a normal gestation, the placenta and the uteroplacental circulation.  This is 
supported by observations that pre-eclampsia occurs primarily in nulliparous women, 
whose subsequent gestations tend to be uncomplicated thereafter, unless there is a change 
in paternity; some evidence that the foetus of pre-eclamptic mothers may be more 
genetically compatible with their mothers than foetus s in normal pregnancies and that 
certain pathologic changes in the placental vasculature resemble those of allograft rejection 
(Laragh & Brenner, 1995). 
 
Further evidence of immunological phenomena has been r ported.  Beginning early in the 
second trimester, women in whom pre-eclampsia develops later have a significantly lower 
proportion of T-helper cells , antibodies against endothelial cells have been found in 50% 
of women with pre-eclampsia versus 15% of control women, deposition of IgM, 
complement (C3) and fibrin have been noted in the walls of pre-eclamptic spiral arteries 
(Dekker & Sibai, 1998). 
 
In the early stages of HIV infection, where few symptoms are seen, there may be a slight 
depression in CD4 T cells which is temporary at this stage.  Immune abnormalities appear 
during the second stage, when the virus begins to replicate at a high level which results in a 
decrease in the percentage and total numbers of CD4 T cells.  The decrease in the CD4 T 
cells remain the most widely used parameter to assess disease progression.  This decrease 
may be due to several factors, including fusion of uninfected T cells with virally infected 
cells, the development of pores in the cell membrane as HIV buds from the cell surface and 
the killing of cells expressing gp120 by cytotoxic lymphocytes programmed to recognise 
this vial protein (Stevens, 1996).   
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Another immune phenomenon is an upset in the balance of ytokines.  In response to the 
presence of HIV, macrophages produce tumour necrosis factor – α (TNF-α) and 
interleukin-1 (IL-1), thereby activating CD4 helper T cells.  Activated helper T cells, in 
turn, produce an array of lymphokines (plays a role cell mediated immunity) which can 
induce viral replication in both infected T cells and macrophages.  As HIV infection 
progresses, the CD4 T-cell population continues to drop, resulting in immunosuppression.  
This results in decreasing signals to multiple limbs of the immune response, so that the 
AIDS patient becomes susceptible to a host of opportunistic infections (Stevens, 1996). 
 
Further, Wimalasundera et al., (2002) proposed that effective ARV treatment may restore a 
HIV infected pregnant woman’s immune response to foetal antigens, and therefore could 
reinstate the pathological processes that result in pre-eclampsia.  Pre-eclampsia may 
therefore be another manifestation on immune restoration, similar to the exacerbation of 
other immune-mediated diseases that follows effectiv  ARV.  The clinical presentation of 
pre-eclampsia and effects of ARV could overlap and complicate diagnosis and 
management in these women.  Conflicting results by Matter et al., (2004), demonstrate that 
pre-eclampsia development is inhibited in HIV seropositive women, and there is a 
possibility that HIV infection inhibits or blocks other factors that may play a role in the 
development of pre-eclampsia. 
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1.5 OBJECTIVE 
 
Current literature suggests that there exists an overlap of haematological abnormalities in 
HIV infected individuals and pre-eclamptic women.  Further to this, it is known that an 
individual’s immune status is debilitated during HIV infection. The immune system is also 
altered during pregnancy and exacerbated in pre-eclampsia. 
 
The focus of this research endeavour is to compare, contrast and evaluate to help better 
understand the haematological and immune manifestations in women with both pre-
eclampsia and HIV.  This study endeavours to assist in creation of a more comprehensive 
tool to evaluate, diagnose and manage women affected with both these diseases and 
improve prognosis and care. 
 
Therefore the objectives are:  
1) Evaluation of haematological parameters in HIV negative pre-eclamptic women. 
2) Evaluation of immune markers in HIV negative pre-eclamptic women. 
3) Evaluation of haematological parameters in HIV positive pre-eclamptic women. 
4) Evaluation of immune markers in HIV positive pre-eclamptic women. 
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2.1 STUDY DESIGN 
 
 
2.2.1 Study Population 
 
Ethical approval for this research study was granted by the University of KwaZulu-Natal 
Ethics Committee on 09 November 2004 (Reference Number H136/04).  Women were 
recruited for this cross-sectional study from King Edward VIII Hospital (KEH) in Kwa-
Zulu Natal, Durban.  The study population comprised of two groups i.e., pre-eclamptic 
HIV-positive African women and pre-eclamptic HIV-negative African women as the 
control group.  HIV-negative and HIV-positive pre-eclamptic women diagnosed with a BP 
≥ 140/90 mmHg (BP measured with Welsh and Allyn Vital Monitors) and proteinuria ≥ 1+ 
at > 24 weeks gestation were screened pre-delivery.  Those that were interested in 
participating voluntarily signed the informed conset which included permission to access 
HIV results.  Women underwent routine HIV screening (Abbott Determine® HIV rapid 
test, USA) at KEH including pre- and post-test counseling.  The HIV status of each woman 
was accessed from the participant’s hospital records.   
 
Pre-eclampsia is a pregnancy-specific syndrome that occurs after 20 weeks gestation.  Pre-
eclampsia is a clinical diagnosis: only women with a BP of ≥ 140/90 mmHg and 
proteinuria ≥ 1+ were included.  A full medical history was taken into account to record 
any additional medical conditions which may affect the parameters being tested.  This did 
not affect recruitment. 
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2.2.2 Statistical Analysis 
 
Sample size was determined as 18 per group.  Group sample sizes of 18 and 18 achieve 
80% power to detect a difference of 440.0 between the null hypothesis that both group 
means are 820.0 and the alternative hypothesis that the mean of group 2 is 380.0 with 
estimated group standard deviations of 600.0 and 200.0, with a significance level (alpha) of 
0.05000. 
 
SPSS version 13 (SPSS Inc., Chicago, Illinois) was used to analyse the data. Bivariate 
analysis was undertaken to assess associations between HIV status and various outcomes. 
Categorical outcomes were assessed using Pearson’s Chi Square tests or Fisher’s Exact 
tests where appropriate. Quantitative outcomes were test d for normality and found to be 
significantly skewed. Thus non-parametric Mann - Whitney tests were used to compare 
median values between HIV negative and positive groups. Distribution of the data in each 
group was graphically presented with box and whisker plots and tabulated showing 
medians, interquartile ranges and percentiles.  A p value of < 0.05 was considered 
statistically significant. 
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2.2.3 Collection of Blood Samples 
 
Pre-eclampsia occurs after 20 weeks gestation, returning to normal within three months 
postpartum.  Any dilution effects from intravenous fluids or blood loss may have affected 
post delivery samples.  Therefore, venous blood samples were collected pre-delivery by 
trained clinical staff into two tubes containing ethylenediaminetetraacetic acid (EDTA), 
which acts as chelating agent and anticoagulant.   Both samples were labelled accordingly 
and transported within an hour of collection to therespective laboratories – Department of 
Haematology, KEH (routine testing) and Department of Optics and Imaging/Department of 
Physiology, University of Kwa-Zulu Natal where samples were processed by trained 
laboratory staff. 
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2.2 EVALUATION OF THE HAEMATOLOGICAL PARAMETERS IN HIV -
INFECTED AND NON-INFECTED PRE-ECLAMPTIC BLACK WOMEN - 
FULL BLOOD COUNT  
 
Haematology is the study of blood cells and the factors that affect their functioning.  The 
cells that circulate in the blood stream are divided into three types:  
 
 white blood cells (WBC’s) (leukocytes), 
 red blood cells (RBC’s) (erythrocytes) and 
 platelets (thrombocytes).  
 
The full blood count (FBC) is an automated count of hese cells and provides information 
on the number, type, size, shape and some of the physical characteristics of the cell.   
 
The FBC was carried out on the Beckman CoulterR HmX Haematology Analyser 
(Beckman Coulter, Florida, USA) (Figure 2.1).  All reagents were purchased from 
Beckman Coulter (Florida, USA).   
 
Calibration procedure was performed using S-CAL calibr tor.  Coulter LatronTM primer 
and control was analysed once at the beginning of each day.  The Cycling Coulter 5C-cell 
control was used to monitor the performance of instruments. 
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Table 2.1: Haematological parameters measured 
 
Parameter Normal Reference Range 
Red Blood Cells 3.5 - 5.0 x10^12/l 
Haemoglobin (Hb) 11.5 - 13.5g/dL 
Haematocrit 37.0 - 52.0% 
Mean Cell Volume (MCV) 78.0 - 99.0 fl 
Mean Cell Haemoglobin (MCH) 27.0 - 32.0 pg 
Mean Cell Haemoglobin Concentration (MCHC) 30.0 - 35.0g/dL 
Red Blood Cell Distribution Width (RDW) 11.5 - 14.5% 
Platelets 150 - 450 x10^9/L 
Mean Platelet Volume (MPV) 7.4 - 10.4 fl 
White Blood Cells (WBC) 4.0 - 11.0 X10^9/L 
Neutrophil (%) 40 - 75% 
Lymphocyte (%) 20 - 45% 
Monocyte (%) 2 - 10% 
Eosinophil (%) 1 - 6% 
Basophil (%) 0 - 1% 
Neutrophil (absolute) 2.0 - 7.5 x10^9/L 
Lymphocyte (absolute) 1.5 - 4.0 x10^9/L 
Monocyte (absolute) 0.5 - 1.5 x10^9/L 
Eosinophil (absolute) 0.04 - 0.4 x10^9/L 
Basophil (absolute) 0.0 - 0.1 x10^9/L 
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2.3 EVALUATION OF THE IMMUNE M ARKERS IN HIV -INFECTED AND 
NON-INFECTED PRE-ECLAMPTIC BLACK WOMEN – FLOW 
CYTOMETRY 
 
The immune system depends upon the recognition of exogenous materials as being foreign 
to the body, known as an antigen.  This results in he activation of the immune system with 
the purpose of neutralising or destroying the antige .  Lymphocytes play a key role in 
immune response and T lymphocytes are divided into functional subsets as identified by 
the presence of different surface markers: 
 
 T helper cells 
 
T helper cells assist other lymphocytes to perform their effector functions by secreting a 
variety of locally acting mediators known as cytokines.  T cells are characterised by the 
surface marker CD4 as well as the pan-T cell markers CD2 and CD3, which are present on 
all mature T cells. 
 
 Cytotoxic T cells 
 
These lymphocytes function in the killing of virus-infected and malignant cells.  Most 
carry the surface marker CD8 as well as the pan-T cell markers. 
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 Suppressor T cells 
 
The exact role of suppressor cells in vivo is unclear but it is thought to be responsible for 
“switching off” the immune response once the initiating stimulus is removed and possibly 
for suppressing immune responsiveness to self-antigens.  Suppressor cells also carry the 
CD8 marker (Young & Heath, 2000). 
 
Flow cytometry is often used to determine the types of markers and receptors on the 
surface of a cell.  It is commonly used in HIV infection to assay the CD3 values, CD4/CD8 
ratio, to evaluate disease progression and monitor therapy (Rose t al., 1992). 
 
A normal immune response requires a balance between th  regulatory activities of several 
interacting cell types – primarily T-helper and T-suppressor cells.  By using highly specific 
antibodies, flow cytometry can analyse several lymphocyte markers including the 
following:  
 
 CD3 – To measure mature T cells when the immune system malfunctions 
 CD4 – To identify and characterise the proportion of T-helper cells in autoimmune 
 or immunoregulatory disorders 
  To detect immunodeficiency disorders such as AIDS 
  To differentiate T-cell acute lymphoblastic leukaemia from T-cell   
  lymphomas and other lymphoproliferative disorders 
 CD8 – To identify and characterise the proportion of T-suppressor cells in auto –  
                        immune and immunoregulatory disorders (McCann, 2002). 
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Flow cytometry is used in a variety of different fields including immunology, pathology 
and medicine.  It is a powerful technique to simultaneously analyse multiple characteristics 
of thousands of individual cells in a relatively short period of time.  Flow cytometry makes 
these multi-parametic measurements on single cells as opposed to population 
measurements (National Institute of Environmental Health Sciences, 2006).  High 
precision and sensitivity, combined with the large numbers of cells that can be examined, 
allow resolution of even minor subpopulations from complex mixtures with high levels of 
statistical validity.  The ability to separate physically these populations by flow sorting 
allows further functional and morphologic correlations (Preffer, 1988). 
 
 
2.3.1 Principles and instrumentation 
 
A suspension of cells stained with two monoclonal antibodies conjugated with either a 
green or orange emitting fluorescent dye is introduced into the laminar flow of a confining 
sheath fluid within the flow cell of a cytometer.  The rapidly moving sheath separates cells 
and ensures individual and uniform interrogation by the precisely focused laser light 



























Figure 2.2: Schematic representation of the instrumentation of a flow cytometer  
         (Decker, 2006) 
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The presence of a cell in the path of the laser scatters light in all directions and excites the 
fluorescent dyes conjugated to the monoclonal antibodies bound to the cell.  This results in 
either reflected or refracted light reaching the detector.  The pattern of light scattering is 
dependent on cell size and shape, giving relative measures of theses cellular characteristics 
as cells flow through the beam (Simmer, 2003). 
 
Fluorescence based detection depends on the absorption of the light by the cell and the 
subsequent re-emission of this light at a different frequency.  Flow cytometers make use of 
this technology by employing filters to block the original light source from reaching the 
detector, while the fluorescence emission is allowed through for detection, which allows a 
very low background of stray light to reach the detector.  Various fluorescent dyes are 
commercially available with the most common dyes used being fluorescein isothiocyanate 
(FITC) and phycoerythrin (PE).  The amount a cell scatters or fluoresces light is measured 
is collected by a light sensitive diode and converted into electronic signals (Simmer, 2003). 
 
 
2.3.2 Display and interpretation of data 
 
Dot plot displays use two parameters to graph the data generated by flow analysis, with 
each dot representing the passage of one cell throug  the detector.  The X- and Y-axes 
measure the different emissions, displaying a dot for each of the cells that show that 
particular emission.  Plots are usually divided into four areas.  A cell of a particular 
population type will show up as a dot in the quadrant of the dot plot designated for that 
population (Simmer, 2003). 
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2.3.3 Flow Cytometry 
 
Due to operational circumstances, samples were processed on the Coulter Epics MCL Flow 
Cytometer (Beckman Coulter, Florida, USA) (Figure 2.3) and the FACSCalibur Flow 
Cytometer (Becton Dickinson, California, USA) (Figure 2.4).  Both these instruments can 
be used interchangeably provided that they are both aligned and standardised correctly. 
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2.3.3.1 Beckman Coulter Epics MCL Flow Cytometer 
 
All reagents were purchased from Beckman Coulter, Florida, USA.  FLOW-CHECK and 
Epics IMMUNO-BRITE beads were used to align and determine linearity/fluorescence 
intensity respectively.  Zones were gated to analyse maximum cells for each sample which 
were expressed as percentage values.  These were conv rted to absolute counts using the 
FBC parameters. 
 
 100ul of sample was aliquoted into 75 x 12 mm polyurethane tubes 
 CYTO-STAT Monoclonal antibodies were added:  
 IgG1 RDI / FITC – isotypic control to exclude non-specific staining 
cells 
 T4 RDI / T8 FITC – specific for CD4 and CD8 
 T3 RDI – specific for CD3 
 The samples were vortexed and allowed to incubate in the dark at room       
 temperature for 30 minutes to allow antigen/antibody binding 
 Following this, the samples were then passed through a Coulter Q-Prep 
 Workstation (Beckman Coulter, Florida, USA) which automatically dispensed: 
 Reagent A – 600ul formic acid (lysing) 
 Reagent B – 265ul sodium chloride, sodium sulphate and sodium 
carbonate (stabilising) 
 Reagent C – 100ul paraformaldehyde (fixing) 
 After preparation on the Coulter Q-Prep Workstation he samples were analysed on 
the flow cytometer 
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2.3.3.2 Becton Dickinson FACSCalibur Flow Cytometer 
 
All reagents and materials were purchased from Becton Dickinson, California, USA.  
CaliBRITE beads and FACSComp were used for setting he photomultiplier tube (PMT) 
voltages, setting the fluorescence compensation and checking the instrument sensitivity.  A 
control was run to optimise instrument settings andperform quality control. 
 
A three-colour direct immunoflourescence reagent, TriTEST CD4 FITC / CD8 PE / CD3 
peridinin chlorophyll protein (PerCP) was used to determine absolute counts of CD4, CD8 
and CD3 together with TruCOUNT Tubes.  TruCOUNT tubes contain a lyphilised pellet 
that dissolves during sample preparation, releasing a known number of fluorescent beads.  
 
By gating the bead population during analysis, MultiSET Software automatically 
calculated subset absolute counts.  MultiSET provided automatic gating using an Expert 
Gate to exclude unwanted cells and debris.   
 
 20ul of TriTEST CD4 / CD8 / CD3 reagent was aliquoted into the TruCOUNT Tube 
 50ul of well-mixed whole blood was thereafter aliquoted into the TruCOUNT Tube 
 Samples were vortexed and incubated for 15 minutes in the dark at room 
temperature  
 450ul FACS Lysing Solution was aliquoted into the tube 
 Samples were vortexed and incubated for 15 minutes in the dark at room 
temperature 
 Samples were then analysed on the flow cytometer 
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3.1 SAMPLE SIZE   
 
Sixty blood samples were obtained with only 46 being processed (Table 3.1).  Of the 46 
samples, 45 were processed for haematological parameters and 33 were processed for 
immune markers.  This was due to operational circumstances leading to samples not being 
processed timeously.  Sample integrity was maintained, the laboratory equipment was 
validated for the 33 samples.  The remaining specimns produced results that could not be 
validated.  
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Table 3.1:  Case processing summary of the sample size for each parameter 
 
Parameters Included HIV (-) HIV (+) Total 
Red Blood Cells 45 25 20 46 
Haemoglobin  45 25 20 46 
Haematocrit  45 25 20 46 
Mean Cell Volume  45 25 20 46 
Mean Cell Haemoglobin 45 25 20 46 
Mean Cell Haemoglobin Conc. 45 25 20 46 
Red Blood Cell Distribution Width 45 25 20 46 
Platelets   45 25 20 46 
Mean Platelet Volume 45 25 20 46 
White Blood Cells 45 25 20 46 
Neutrophils (%) 45 25 20 46 
Lymphocytes (%) 45 25 20 46 
Monocytes (%) 45 25 20 46 
Eosinophils (%) 45 25 20 46 
Basophils (%) 45 25 20 46 
Neutrophils (absolute) 44 25 19 46 
Lymphocytes (absolute) 45 25 20 46 
Monocytes (absolute) 44 25 19 46 
Eosinophils (absolute) 45 25 20 46 
Basophils (absolute) 45 25 20 46 
CD3 (absolute) 33 18 15 46 
CD4 (absolute) 33 18 15 46 
CD8 (absolute) 33 18 15 46 
 
HIV (-) – Human Immunodeficiency Virus negative  
HIV (+) – Human Immunodeficiency Virus positive  
Total samples = 100%
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3.2 CLINICAL DATA 
 
There was no statistical significance (p < 0.05) betwe n both groups, in respect of the 
maternal clinical data (Table 3.2).  Among the HIV-negative pre-eclamptic group, 48.0% 
were ≤ 24 years and 52.0% were > 24 years.  Among the HIV-positive pre-eclamptic 
group, 28.6% were ≤ 24 years and 71.4% were > 24 years (p=0.179).  Among the HIV-
negative pre-eclamptic group, 52.0% were nulliparous and 48.0% had ≥ 1 child previously.  
Among the HIV-positive pre-eclamptic group, 23.8% were nulliparous and 76.2% had ≥ 1 
child previously (p=0.051).  There was a trend towards statistical significance in respect to 
parity. 
 
Among the HIV-negative pre-eclamptic group, 52.0%, 40.0% and 8.0% had proteinuria of 
2+, 3+ and 4+ respectively.  Among the HIV-positive pr -eclamptic group, 47.6%, 52.4% 
and 0.0% had proteinuria of 2+, 3+ and 4+ respectivly (p=0.349).  Among the HIV-
negative pre-eclamptic group, 60.0% were at a gestational age between 24 – 36 weeks and 
40.0% were >36 weeks.  Among the HIV-positive pre-eclamptic group, 61.9% were at a 
gestational age between 24 – 36 weeks and 38.1% were >36 weeks (p=0.895). 
 
Among the HIV-negative pre-eclamptic group, 68.0% had a caesarean section (CS) and 
32.0% had normal vaginal delivery (NVD) as compared to the HIV-positive pre-eclamptic 
group where 52.4% had a CS and 47.6% had NVD (p=0.280).  Among the HIV-negative 
pre-eclamptic group, 40.0% had a BP of <160/110 mmHg and 60.0% had a BP of 
>160/110 mmHg.  Among the HIV-positive pre-eclamptic group, 38.1% had a BP of 
<160/110 mmHg and 61.9% had a BP of >160/110 mmHg (p=0.895). 
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Table 3.2:  HIV status versus maternal clinical data 
 
Clinical Data HIV Negative HIV Positive P value 
≤ 24 n = 12 (48.0%)  n = 6 (28.6%) Age Group 
(years) > 24 n = 13 (52.0%) n = 15 (71.4%) 
0.179 (NS) 
Nulliparous n = 13 (52.0%)  n = 5 (23.8%) 
Parity 
≥ 1 n = 12 (48.0%) n = 16 (76.2%) 
0.051 (NS) 
2+ n = 13 (52.0%) n = 10 (47.6%) 
3+ n = 10 (40.0%) n = 11 (52.4%) Proteinuria 
4+  n = 2 (8.0%)  n = 0 (0.0%) 
0.349 (NS) 
24 – 36 n = 15 (60.0%) n = 13 (61.9%) Gestational age 
(weeks) > 36 n = 10 (38.1%)  n = 8 (38.1%) 
0.895 (NS) 
CS n = 17 (68.0%) n = 11 (52.4%) Mode of 
Delivery NVD  n = 8 (32.0%) n = 10 (47.6%) 
0.280 (NS) 
< 160/110 n = 10 (40.0%)  n = 8 (38.1%) Blood Pressure 
(mmHg) > 160/110 n = 15 (60.0%) n = 13 (61.9%) 
0.895 (NS) 
 
CS – caesarean section 
NVD – normal vaginal delivery 
HIV – Human Immunodeficiency Virus 
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There was no statistical significance (p < 0.05) betwe n the groups in respect of foetal 
clinical data (Table 3.3).  Among the HIV-negative pre-eclamptic group, 68.0% gave birth 
to babies with a weight of ≤2500 grams and 32.0% to >2500 grams.  Among the HIV-
positive pre-eclamptic group, 61.9% gave birth to babies with a weight of ≤2500 grams and 
38.1% to >2500 grams (p=0.665).  Among the HIV-negative pre-eclamptic group, 88.0% 
and 12.0% had baby outcomes of alive and deceased respectively.  Among the HIV-
positive pre-eclamptic group, 85.7% and 14.3% had bby outcomes of alive and deceased 
respectively (p=0.819).  
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Table 3.3:  HIV status versus foetal clinical data 
 
Clinical Data HIV Negative HIV Positive P value 
≤ 2500 n = 17 (68.0%) n = 13 (61.9%) Weight of 
Baby (grams) > 2500  n = 8 (32.0%)   n = 8 (38.1%) 
0.665 (NS) 
Alive  n = 22 (88.0%)  n = 18 (85.7%) 
Baby Outcome 
Deceased  n = 3 (12.0%) n = 3 (14.3%) 
0.819 (NS) 
 
HIV – Human Immunodeficiency Virus 
NS – Not significant 
HIV Negative deceased = Early neo-natal death (n=2), macerated stillbirth (n=1) 
HIV Positive deceased = Macerated stillbirth (n=2), fresh stillbirth (n=1) 
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3.3 HAEMATOLOGICAL PARAMETERS 
 
There was no statistical significance (p < 0.05) in haematological parameters between both 
the groups (Table 3.4).  Red blood cells are within e normal reference values of 3.5 – 5.0 
x 10^12/l in both groups, HIV-negative = 3.91 x 10^2/l and HIV-positive = 3.79 x 
10^12/l (p=0.522).  Haemoglobin was within the normal reference values of 11.5 – 13.5 
g/dL in the HIV-negative group, 11.5 g/dL and slightly lower than normal in the HIV-
positive group, 11.1 g/dL but cannot be considered clinically significant (p=0.576). 
 
Haematocrit was slightly lower in both groups as compared to the normal reference values 
of 37.0 – 52.0 % but not clinical significant.  In the HIV-negative group, haematocrit was 
34.1% and in the HIV-positive group, haematocrit was 33.2% (p=0.545).  Mean cell 
volume was within the normal reference values of 78.0 – 99.0 fl in both groups, HIV-
negative = 87.4 fl and HIV-positive = 87.5 fl (p=0.664).  Mean cell haemoglobin was 
within the normal reference values of 27.0 – 32.0 pg in both groups, HIV-negative = 29.3 
pg and HIV-positive = 30.3 pg (p=0.320).  Mean cell haemoglobin concentration was also 
within the normal reference values of 30.0 – 35.0 g/dL in both groups, HIV-negative = 
34.1 g/dL and HIV-positive = 34.3 g/dL (p=0.873).  Red cell distribution width was within 
the normal reference values of 11.5 – 15.5 % in both groups, HIV-negative = 14.4 % and 
HIV-positive = 14.5 % (p=0.936).   
 
Platelets were within the normal reference values of 150 – 450 x 10^9/L in both groups, 
HIV-negative = 205 x 10^9/L and HIV-positive = 225 X 10^9/L (p=0.749).  Mean platelet 
volume was within the normal reference values of 7.4 – 10.4 fl in both groups, HIV-
negative = 9.5 fl and HIV-positive = 9.6 fl (p=0.373).   
 
   79 
Table 3.4:  Red blood cell and platelet parameters among HIV-negative and HIV- 
  positive pre-eclamptic women 
 
Parameters HIV Negative HIV Positive P value 
Minimum 3.09 2.43 
Median 3.91 3.79 
Red Blood Cells 
(3.5 - 5.0 x10^12/l) 
Maximum 4.78 4.53 
0.522 
(NS) 
Minimum 8.30 7.60 
Median 11.50 11.10 
Haemoglobin   
(11.5 - 13.5g/dL) 
Maximum 14.50 13.70 
0.576 
(NS) 
Minimum 25.80 21.40 
Median 34.10 33.20 
Haematocrit     
(37.0 - 52.0%) 
Maximum 42.10 38.80 
0.545 
(NS) 
Minimum 70.30 67.50 
Median 87.40 87.50 
Mean Cell Volume            
(78.0 - 99.0 fl) 
Maximum 95.10 96.90 
0.664 
(NS) 
Minimum 21.40 21.70 
Median 29.30 30.30 
Mean Cell 
Haemoglobin    
(27.0 - 32.0 pg) Maximum 35.20 32.50 
0.320 
(NS) 
Minimum 30.40 30.50 
Median 34.10 34.30 
Mean Cell Hb 
Concentration   
(30.0 - 35.0g/dL) Maximum 37.10 35.90 
0.873 
(NS) 
Minimum 12.50 13.00 
Median 14.40 14.55 
RDW                  
(11.5 - 14.5%) 
Maximum 24.60 21.10 
0.936 
(NS) 
Platelets             Minimum 123.00 95.00 0.749 
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Median 205.00 225.00 (150 - 450 x10^9/L) 
Maximum 458.00 431.00 
(NS) 
Minimum 7.30 7.40 
Median 9.50 9.65 
Maximum 12.30 14.50 
Mean Platelet 
Volume               
(7.4 - 10.4 fl) 




HIV – Human Immunodeficiency Virus 
NS – Not significant 
Hb – Haemoglobin  
RDW – Red Blood Cell Distribution Width 
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White blood cells were within the normal reference values of 4.0-11.0 x 10^9/L in both 
groups, HIV-negative = 10.8 x 10^9/L and HIV-positive = 9.0 x 10^9/L (p=0.201) (Table 
3.5).  Neutrophils (%) were slightly higher in the HIV-negative group, 76.7% as compared 
to the normal reference values of 40 – 75%, indicative of slight neutrophilia.  In the HIV-
positive group, neutrophils (%) were within the normal reference values, 71.2% (p=0.249).  
 
Lymphocytes (%) were slightly lower (lymphopenia) in the HIV-negative group, 17.0% as 
compared to the normal reference values of 20 – 45%.  In the HIV-positive group, 
lymphocytes (%) were within the normal reference values (p=0.226).  Monocytes (%) were 
within the normal reference values of 2.0 – 10.0 % in both groups, HIV-negative = 4.0% 
and HIV-positive = 4.2% (p=0.304). 
 
Eosinophils (%) were slightly lower in both groups a  compared to the normal reference 
values of 1 – 6 %, indicative of eosinopenia.  In the HIV-negative group, eosinophils (%) 
were 0.7% and in the HIV-positive group, eosinophils (%) were 0.9% (p=0.162).  
Basophils (%) were within the normal reference values of 0 – 1.0 % in both groups, HIV-
negative = 0.3% and HIV-positive = 0.32% (p=0.564). 
 
Neutrophils (absolute) were slightly higher, neutrophilia, in the HIV-negative group, 7.8 x 
10^9/L, as compared to the normal reference values of 2.0-7.5 x 10^9/L.  In the HIV-
positive group, neutrophils (absolute) were 6.2 x 10^9/L, within the normal reference 
values (p=0.145).  Lymphocytes (absolute) were within e normal reference values of 1.5-
4.0 x 10^9/L in both groups, HIV-negative and HIV-positive = 1.6 x 10^9/L (p=0.918).   
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Monocytes (absolute) were slightly lower in both groups as compared to the normal 
reference values of 0.5-1.5 x 10^9/L suggestive of possible monocytopenia.  In the HIV-
negative and HIV-postive group, monocytes (absolute) 0.4 x 10^9/L (p=0.607).  
Eosinophils (absolute) were within the normal refernce values of 0.04-0.4 x10^9/L in both 
groups, HIV-negative and HIV-positive = 0.1 x 10^9/L (p=0.623).  Basophil (absolute) 
was constant (count = 0.00) when HIV status was positive.  It has been omitted. 
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Table 3.5:  White blood cell parameters among HIV-negative and HIV-positive  
  pre-eclamptic women 
Parameters HIV Negative HIV Positive P value 
Minimum 5.00 4.60 
Median 10.80 9.05 
White Blood Cells 
(4.0 - 11.0 X10^9/L) 
Maximum 22.70 17.00 
0.201 
(NS) 
Minimum 49.20 36.00 
Median 76.70 71.25 
Neutrophils         
(40 - 75%) 
Maximum 91.50 88.60 
0.249 
(NS) 
Minimum 6.40 6.50 
Median 17.00 21.15 
Lymphocytes      
(20 - 45%) 
Maximum 41.20 47.00 
0.226 
(NS) 
Minimum 0.60 1.10 
Median 4.00 4.25 
Monocytes             
(2 - 10%) 
Maximum 17.00 14.00 
0.304 
(NS) 
Minimum 0.10 0.10 
Median 0.70 0.90 
Eosinophils            
(1 - 6%) 
Maximum 2.40 4.60 
0.162 
(NS) 
Minimum 0.00 0.10 
Median 0.30 0.20 
Basophils               
(0 - 1%) 
Maximum 0.50 0.80 
0.564 
(NS) 
Minimum 2.50 2.20 
Median 7.80 6.20 
Neutrophils 
(absolute)            
(2.0 - 7.5 x10^9/L) Maximum 20.70 14.20 
0.145 
(NS) 
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Minimum 1.00 0.90 
Median 1.60 1.60 
 
Lymphocytes 
(absolute)            





Minimum 0.10 0.10 
Median 0.40 0.40 
Monocytes 
(absolute)            
(0.5 - 1.5 x10^9/L) Maximum 1.30 1.00 
0.607 
(NS) 
Minimum 0.00 0.00 
Median 0.10 0.10 
Eosinophils 
(absolute)          




HIV – Human Immunodeficiency Virus 
NS – Not significant 
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3.4 IMMUNOLOGICAL MARKERS 
 
There was a statistical significance as well as a clinical significance in CD3 (p=0.015) and 
CD4 (p=0.002) between both the groups.  In the HIV-negative group and HIV-positive 
group, the CD3 count was 1423 and 978 respectively (normal reference values = 800 – 
2800 cells/ul) (Table 3.6, Figure 3.1) and CD4 count was 925 and 274 respectively (normal 
reference values = 550 – 1955 cells/ul) (Table 3.6,Figure 3.2).  There was no statistical 
significance in CD8 between both the groups (p=0.842), HIV-negative group = 618.5 
cells/ul and HIV-positive group = 633.0 cells/ul (normal reference values = 250 – 1200 
cells/ul) (Table 3.6). 
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Table 3.6:  Immune markers among HIV-negative and HIV-positive pre-eclamptic 
women 
 
Parameters HIV Negative HIV Positive P value 
Minimum 674.00 338.00 
Median 1423.00 978.00 
CD3 (absolute)    
(800 – 2800 cells/ul)     
Maximum 2712.00 2284.00 
0.015 (S) 
Minimum 176.00 96.00 
Median 925.00 274.00 
CD4 (absolute)  
(550 – 1955 cells/ul) 
Maximum 1716.00 782.00 
0.002 (S) 
Minimum 114.00 110.00 
Median 618.50 633.00 
CD8 (absolute)  
(250 – 1200 cells/ul) 
Maximum 921.00 1333.00 
0.842(NS) 
 
HIV – Human Immunodeficiency Virus 



























Figure 3.1: Graphically representation of CD3 (absolute) distribution among HIV-


































Figure 3.2: Graphically representation of CD4 (absolute) distribution among HIV-
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 No Difference in Maternal Demography 
 
There was no statistical significance in age among the two groups (Table 3.2). However, 
the difference in > 24 years old among the HIV-positive group from 28.6% to 71.4% is in 
keeping with statistics reported by the South African Department of Health where the 
highest prevalence among antenatal clinic attendees w re reported amongst the 25 – 29 and 
30 – 34 year age groups (South African Department of Health, 2005). 
 
There was no statistical significance in parity among both the groups (Table 3.2).  It has 
been suggested that the pathophysiology of pre-eclampsia differs according to parity.  
Barden et al. (1999), however, reported lack of differences in birthweight and biochemical 
and endothelial markers in pre-eclamptic primigravid  and multigravida groups which 
contradicts other studies.  Among the HIV-positive pre-eclamptic group, 23.8% were 
nulliparous and 76.6% had a parity of ≥ 1.  Women with previous pregnancies may suggest 
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 No Difference in Pregnancy Outcomes 
 
It is known that elective CS is the best option in HIV-positive women to reduce the risk of 
mother to child transmission (Mohlala et al., 2005).  There was no statistical difference in 
mode of delivery between both the groups (Table 3.2).  It is not standard practice in the 
public sector hospitals in Durban to perform routine elective CS for HIV positive pregnant 
women at the time of the study and this probably accounted for the lack of difference 
between the groups.  The possible mechanisms for vertical transmission during the 
peripartum (before, during or after giving birth) include transplacental microtransfusions of 
maternal blood into the foetal circulation during contractions, labour and separation of the 
placenta before clamping of the umbilical cord, ascending infection from the vagina 
through the cervix after rupture of the amniotic fluid and absorption of the virus through 
the infants immature digestive tract (Mohlala et al., 2005).   
 
There was no statistical significance in gestational age among both the groups (Table 3.2).  
Pre-eclampsia occurs > 20 weeks gestation, but is not pecific to any particular gestational 
period after 20 weeks gestation.  Pre-eclampsia did not present itself earlier during the 
gestational period due to HIV infection. 
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 No Difference in Clinical Parameters 
 
Women with BP of > 160/110 mmHg were slightly higher between the two groups as 
compared to < 160/110 mmHg but this was not statistical significant (Table 3.2).   
Increased BP in pre-eclampsia is mainly due to a reversal of the vasodilation characteristics 
of normal pregnancy replaced by marked increases in peripheral vascular resistance 
(NHBPEP, 2000).  Studies have shown no association of HIV infection with hypertension 
(Jung et al., 2004). 
 
There was no statistical significance in proteinuria (Table 3.2) among both the groups.  As 
mentioned previously, proteinuria is key feature in pre-eclampsia.  Proteinuria can also be 
linked to HIV infection among patients with HIV-associated nephropathy and renal failure 
which could be the reason as to why there was no difference in proteinuria between both 
the groups (Szczech et al., 2002).   
 
 
 No Difference in Birth Outcomes 
 
There was no statistical significance in the weight of the baby (Table 3.3) and baby 
outcome (alive or deceased) (Table 3.3) between both the groups.  Low birth weight due to 
placental insufficiency has been reported frequently among women with pre-eclampsia, 
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 No Difference in Haematological Parameters 
 
Leukopenia (low WBC) in usually noticed during late stages of HIV infection due to a 
parallel decline in the most numerous WBC’s, neutrophils, lymphocytes and monocytes.  It 
is suggested that lymphopenia and monocytopenia (HIV-1 can be recovered from 
monocytes) results from a direct attack on the cells by HIV through CD4 sites (McPhedran, 
1999).  There was no statistical difference in the lymphocyte, monocyte and neutrophil 
counts shown in Table 3.5, however lymphocytes (%) and neutrophils (absolute and %) in 
the HIV-negative group were observed to be slightly lower than the normal reference 
values. Further, lower monocytes (absolute) were observed in both groups.  No severe 
decline among the HIV-positive group may have been due to it being early stages of 
infection. 
    
The slightly higher neutrophils (absolute and %) in the HIV-negative group could support 
the theory that neutrophils are activated in both the placental bed and maternal circulation 
of women with pre-eclampsia.  Neutrophil activation is associated with a free radical 
release that can either affect endothelial function directly or contribute indirectly through 
production of lipid peroxides.  It is not known whet r a circulating factor is responsible 
for the neutrophil activation and any subsequent lipid peroxidation.  It may also be due to 
exposure to hypoxic conditions or local inflammatory agents encountered during passage 
of neutrophils through the placental circulation.  An alternative explanation is that 
neutrophils obtained from pre-eclamptic women are sensitised to circulating serum factors, 
whereas neutrohils obtained in the non-pregnant state are not (Barden et al., 2001). 
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There was no statistical difference in eosinophils and basophils (absolute and %) between 
both the groups (Table 3.5) suggesting that these parameters are not affected in pre-
eclampsia.      
  
There was no statistical significance in platelets and MPV between the two groups (Table 
3.4).  In pre-eclampsia, thrombocytopenia is the most common haematological 
abnormality.  Platelet counts < 100 000 cells/mm3 are indicative of serious disease.  The 
cause is unclear but it has variously been ascribed to platelet deposition at sites of 
endothelial damage and to an immunological process (Laragh & Brenner, 1995).   
 
Thrombocytopenia is also evident in HIV infection.  Possible aetiologies include immune-
mediated destruction, thrombotic thrombocytopenic purpura, impaired haematopoiesis 
(formation of blood cells) and toxic effects of medication.  In many instances, 
thrombocytopenia is associated with a normal or higher number of megakaryocytes (source 
of blood platelets) in the bone marrow and elevated l vels of platelet associated 
immunoglobulin.  These patients have the clinical syndrome known as immune 
thrombocytopenic purpura (ITP) (Northfelt, 1998).  The possible reason as to why pre-
eclampsia and/or HIV infection showed no effect on platelets may be due to it being early 
stages of HIV infection or mild (not severe) severe p -eclampsia. 
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There was no statistical significance in the RBC’s between both the groups (Table 3.4).  
Red blood cells contain Hb and reduction in these parameters could result in anaemia.  
Anaemia is common in pregnancy due to increased foetal d mand (Chotnopparatpattara et 
al., 2003) and in HIV infection where a persistently low Hb is predictive of a poor 
outcome.   Haemoglobin was slightly lower among the HIV-positive pre-eclamptic group 
but not indicative of severe anaemia (Table 3.4).  Anaemia is the most common finding in 
people with advanced stages of HIV and can be defined as a reduction below normal of the 
haemoglobin concentration and red blood cell mass (Kline, 2005). 
 
In pre-eclampsia, higher Hb concentrations have been r ported.  Failure of the plasma 
volume to expand and subsequently, the Hb concentration to drop is associated with ≤ 3-
fold increase in the incidence of pre-eclampsia in pregnancy (Steer, 2000).  However, the 
results in this study showed that pre-eclampsia and HIV infection had no effect on Hb, 
again, suggesting early stages of HIV infection and/or mild pre-eclampsia. 
 
One of the reported features in pre-eclampsia is impa red blood rheology (deformation and 
flow) due to altered RBC aggregation and deformability.  However, in a study by Pepple et 
al. (2001), no statistical difference in RBC’s among contr l groups and pre-eclamptics was 
found suggesting that RBC aggregation and deformability are not altered in pre-eclampsia 
in keeping with the results obtained in this study.  Further investigation is recommended.   
 
   96 
Haematocrit was slightly lower than the normal refence value between both groups but 
was not statistically significant (Table 3.4).  Haematocrit is the percentage of the volume of 
whole blood that is composed of RBC’s.  Haematocrit values have been reported to be low 
in HIV infection, especially late during the course of infection, related to compromised 
nutritional and antioxidant status (Bogden t al., 2000).  Anim-Nyame et al. (2000) 
reported no difference in haematocrit values in normal pregnant and pre-eclamptic women. 
 
Pre-eclampsia and HIV infection showed no effect on MCV, MCH, MCHC and RDW  
(Table 3.4) which could be attributed to the normal v lues observed for RBC’s, 
haematocrit and Hb since MCV, MCH, MCHC and RDW arecalculated automatically 
from RBC’s, haematocrit and Hb.   
 
 
 Significant Difference in Immunological Parameters 
 
The vascular endothelium plays a role in the maintenance of immune response therefore 
endothelial dysfunction during pre-eclampsia results in immunological alterations to some 
degree (Cetiner et al., 1998).  Further to this, the immune responsiveness of women is 
altered during pregnancy in order to retain protectiv  properties against disease and also 
allow tolerance of the foetus.  Diseases such as pre-eclampsia have been suggested to arise 
as a result of maladaptations in theses immune alterations (Mahmoud et al., 2003). 
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There was a statistical significance in CD3 and CD4 between both the groups (Table 3.6, 
Figure 3.1, Figure 3.2).  However, the CD3 and CD4 counts were within the normal 
reference values in the HIV-negative pre-eclamptic group and even though CD3 was lower, 
it was still within the normal reference values in the HIV-positive pre-eclamptic group, 
with CD4 below the normal reference values in the HIV-positive pre-eclamptic group.  This 
suggests that immune mechanisms involving CD estimations do not play a role in pre-
eclampsia since the decline in the counts can be solely attributed to HIV infection.  There 
was no statistical difference in CD8 among both the groups.  This is in keeping with results 
reported by Cetiner et al. (1998), where no statistical significance in CD4 and CD8 was 
found in pre-eclampsia when compared to normal pregnant controls.   
 
Further, their study found decreased levels of NK cells in pre-eclamptic women than in 
normal pregnant women which may be involved in the pathomechanism of pre-eclampsia.  
However, contradicting results by Mahmoud et al. (2003) showed a statistical significance 
in the number of T lymphocytes: CD2, CD3, CD4, CD8 and CD19.   These findings 
suggested systemic alteration in maternal immunity associated with the pre-eclamptic state.  
The difference in results could be due to the small s mple size used by Mahmoud et al, 
(2003), of the 54 women with pregnancy-induced hypertension, only 14 were protein uric 
and therefore pre-eclamptic.  In this study, 45 samples were evaluated in each pre-
eclamptic HIV-negative and HIV-positive group.   
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The results show HIV infection lowered CD3 and CD4 during pregnancy.  Ibrahim et al. 
(2004), showed no deterioration in the CD4 count in any of the trimesters among HIV 
infected pregnant women, and seemed to only increase po t delivery. The reasoning for 
this, suggested by Ibrahim et al. (2004), may have been due to the cross sectional nature of 
the study.  Further, with the exception of the third trimester CD8 counts, among all the 
trimesters the CD4 and CD8 counts showed significant differences between the HIV-
infected and non-infected pregnant groups. These low r CD4 counts in the HIV-infected 
group might reflect a longer period of infection prior to parturition.   
 
The hallmark of HIV infection is declining CD cell numbers.  The rate of CD4 depletion 
differs among individuals and occurs in four stages: 
 
 A rapid decline for 12 to 18 months at the time of seroconversion 
 A gradual decline over several years during the asymptomatic period 
 A more rapid decline which can last at least several months just before AIDS 
develops 
 Continued CD4 decline until death. 
 
CD8 numbers are usually elevated in HIV infection.  This occurs during the first few 
months of infection but remains fairly stable thereaft r (Rose et al., 1992).  This may be 
reason as to why the CD8 count is within the normal range in the HIV – positive group.  
Abnormally low CD3 counts herald the final stages of disease progression and since it may 
have been early stages of HIV infection, this was not observed. 
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Also of note, are the low CD4 counts but normal WBC (Table 3.5) and lymphocyte counts 
in the HIV-positive group suggesting early HIV infection.  Throughout the period of HIV 
infection, until AIDS develops, total WBC, lymphocyte (absolute and percentage) counts 
remain relatively stable and are comparable to levels in healthy normal controls.  Only late 
in HIV infection, a decrease is noted in these parameters (Rose t al., 1992).   

















   101 
Results obtained in this study do not show any severe haematological or immunological 
abnormalities when women have both pre-eclampsia and HIV infection.  Haematological 
manifestations i.e. anaemia, thrombocytopenia and leukopenia, key features in either pre-
eclampsia or HIV infection were not observed.  The decrease in CD3 and CD4 counts can 
be attributed solely to HIV infection.  No other immunological alterations were noted 
suggesting that the immune mechanisms do not play a role in the development of pre-
eclampsia.   
 
Therefore, these results suggest that a more specific management is not required when 
women have both pre-eclampsia and HIV infection.  Medical care should be administered 
on the basis of grade of pre-eclampsia (mild or severe) and stage of HIV infection taking 
into account maternal and foetal well-being. 
 
Results obtained from this study contradict outcomes of other studies conducted.  Further 
investigation is warranted in these areas.  Limitations to this study may include small 
sample size and neglected ARV treatment history amongst the HIV-positive group, which 
may have played a role in the stability of the haemtological parameters.  Also, tracking 
the women over all three trimesters may have produce  more significant results.  Due to 
the small sample size, this study may serve to determin  the study size required for a larger 
study to evaluate the hematological parameters and immune markers among HIV-infected 
and non-infected pre-eclamptic women in South Africa. 
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